Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/jth.14954 http://scihub22266oqcxt.onion/10.1111/jth.14954 32526092!7307111!32526092     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Thromb+Haemost 2020 ; 18 (9): 2202-2204 Nephropedia Template TP {{tp|p=32526092|t=2020. Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis |pdf=|usr=}}{{32526092}} gab.com Text Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis JO: J Thromb Haemost http://www.kidney.de/pget.php?&tw=1&pmid=32526092 #FOAvip COVID-19 can be associated with coagulopathy (CAC, COVID-19-associated coagulopathy) with a high prothrombotic risk based on an intense inflammatory response to viral infection leading to immunothrombosis through different procoagulant pathways. Emerging evidence suggests that the use of heparin in these patients could be associated with lower mortality. Emicizumab is a bispecific humanized monoclonal antibody that bridges activated factor IX and factor X, thereby restoring the function of missing factor VIIIa in hemophilia A. The use of emicizumab has been associated with thrombotic events in patients who also received high cumulative amounts of activated prothrombin complex concentrates. Although this risk is extremely low, there is a lack of evidence on whether CAC increases the thrombotic risk in patients on emicizumab prophylaxis. We present the case of a patient with severe hemophilia A in prophylaxis treatment with emicizumab; due to the potential thrombotic risk we decided to administer low molecular weight heparin as prophylaxis treatment without any thrombotic or bleeding complications. Twit Text FOAVip Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis ????J Thromb Haemost http://www.kidney.de/pget.php?&tw=1&pmid=32526092 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32526092 #FOAvip English Wikipedia <ref>{{Cite pmid|32526092}}</ref> Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis #MMPMID32526092 Rivas-Pollmar MI; Alvarez-Roman MT; Butta-Coll NV; Martin Salces M; Garcia-Barcenilla S; Jimenez-Yuste V J Thromb Haemost 2020[Sep]; 18 (9): 2202-2204 PMID32526092show ga COVID-19 can be associated with coagulopathy (CAC, COVID-19-associated coagulopathy) with a high prothrombotic risk based on an intense inflammatory response to viral infection leading to immunothrombosis through different procoagulant pathways. Emerging evidence suggests that the use of heparin in these patients could be associated with lower mortality. Emicizumab is a bispecific humanized monoclonal antibody that bridges activated factor IX and factor X, thereby restoring the function of missing factor VIIIa in hemophilia A. The use of emicizumab has been associated with thrombotic events in patients who also received high cumulative amounts of activated prothrombin complex concentrates. Although this risk is extremely low, there is a lack of evidence on whether CAC increases the thrombotic risk in patients on emicizumab prophylaxis. We present the case of a patient with severe hemophilia A in prophylaxis treatment with emicizumab; due to the potential thrombotic risk we decided to administer low molecular weight heparin as prophylaxis treatment without any thrombotic or bleeding complications. |Antibodies, Bispecific/*therapeutic use[MESH] |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH] |Anticoagulants/therapeutic use[MESH] |Blood Coagulation[MESH] |COVID-19/*complications[MESH] |Coagulants[MESH] |Factor IXa/chemistry[MESH] |Factor X/chemistry[MESH] |Follow-Up Studies[MESH] |HIV Infections/complications[MESH] |Hemophilia A/*complications/*drug therapy[MESH] |Hepatitis C/complications[MESH] |Humans[MESH] |Inflammation[MESH] |Lymphoma, Non-Hodgkin/complications[MESH] |Male[MESH] |Middle Aged[MESH] |Thrombosis[MESH]Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A (epmc).pdf DeepDyve Pubget Overpricing